Improving metabolic health by enhancing the release of beneficial lipids through the skin
Engineering the release of oxylipins through the skin
This study is looking at a new way to help people with obesity and type 2 diabetes by boosting a helpful fat molecule in the body that can improve how we manage weight and sugar levels, using a special technique that works through the skin.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11090393 on NIH RePORTER |
What this research studies
This research focuses on addressing obesity and type 2 diabetes by exploring how to enhance the release of specific signaling lipids called oxylipins from adipose tissue. The approach involves a novel technique known as tissue nanotransfection, which aims to increase the levels of a beneficial oxylipin, 12,13-diHOME, that plays a crucial role in regulating metabolism. By improving the release of this lipid, the research seeks to positively impact glucose and fatty acid metabolism, potentially leading to better management of weight and metabolic health. Patients may benefit from this innovative method that targets metabolic regulation through the skin.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with obesity or type 2 diabetes who are looking for innovative treatment options.
Not a fit: Patients who are not overweight or do not have type 2 diabetes may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing obesity and type 2 diabetes, improving overall metabolic health.
How similar studies have performed: While the approach of enhancing lipid release through the skin is relatively novel, previous studies have shown promise in using similar methods to influence metabolic health.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Stanford, Kristin I — Ohio State University
- Study coordinator: Stanford, Kristin I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.